Mannkind Corp
MNKD
Market Cap$1.25B
Close$
$4.94
7.6% upside
Current Fair Value
7.6% upsideUndervalued by 7.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.25 Billion |
|---|---|
| Enterprise Value | $1.32 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.03 |
| Beta | 1.15 |
| Outstanding Shares | 272,315,846 |
| Avg 30 Day Volume | 1,922,056 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 147.28 |
|---|---|
| PEG | -70.63 |
| Price to Sales | - |
| Price to Book Ratio | -4.59 |
| Enterprise Value to Revenue | 5.87 |
| Enterprise Value to EBIT | 42.55 |
| Enterprise Value to Net Income | 155 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | -1.6 |
Revenue Sources
No data
ESG Score
No data
About Mannkind Corp
233 employees
CEO: Michael Castagna MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder,...